The Role of Lymphocytes in the Development and Treatment of Alopecia Areata
As we know, Alopecia Areata is disease where the person’s own immune system attacks their hair follicles. This self-attack is known as
Concert Pharmaceuticals Releases Information on Upcoming CTP-543 Phase 3 Trials
Leading off of the Phase 2 CTP-543 trials, Chief Development Officer of Concert Pharmaceuticals, Dr. James V. Cassella states: “The planned initiation
Phase 2 of CTP-543 Trial Brings Positive News
Positive results have been reported following the completion of the CTP-543 Phase 2 trial. More than 75% of patients receiving two daily